Related Experiment Videos
[Clinical experience with sustained release cephalexin (S-6437) in pediatrics (author's transl)]
Insights
Sustained release cephalexin granules (S-6437) demonstrated prolonged effective blood levels in pediatric patients, outperforming standard dry syrup. This new formulation showed an 88.6% efficacy rate across various infections with minimal accumulation and manageable side effects.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Drug Delivery Systems
Context:
- Cephalexin is a widely used antibiotic for bacterial infections.
- Pediatric formulations require careful consideration of dosing and sustained release properties.
- Optimizing antibiotic delivery can improve treatment outcomes and patient compliance.
Purpose:
- To evaluate the pharmacokinetic profile and clinical efficacy of S-6437, a sustained-release cephalexin granule formulation for pediatric use.
- To compare the sustained release profile of S-6437 with conventional cephalexin dry syrup.
- To assess the safety and tolerability of S-6437 in children.
Summary:
- Single oral administration of S-6437 (25 mg/kg) in children aged 4-6 years resulted in sustained therapeutic cephalexin blood levels for up to 12 hours, exceeding those of regular cephalexin dry syrup.
- S-6437 was administered to 38 pediatric patients with infections including pneumonia, bronchitis, and tonsillitis, achieving an 88.6% response rate.
- Observed side effects were transient, including diarrhea and rash, with no evidence of drug accumulation in the body.
Impact:
- S-6437 offers a promising sustained-release option for pediatric cephalexin therapy, potentially improving treatment adherence and efficacy.
- The study supports the development of advanced drug delivery systems for pediatric antibiotic treatment.
- Further research may explore broader applications and long-term safety of S-6437.
Abstract:
S-6437 (Sustained release cephalexin granule for pediatric use) was studied with the following results: 1) Following the single oral administration of 25 mg/kg of S-6437 in 6 children 4 approximately 6 years old, the following blood levels (average) of cephalexin were obtained: 3.1 microgram/ml in one hour after the administration, 8.6 microgram/ml in 2 hours, 8.7 in 4 hours, 7.2 in 6 hours, 4.0 in 8 hours and 1.2 in 12 hours. Effective blood levels of cephalexin by S-6437 were maintained for longer period of time than those by regular cephalexine dry syrup. In 4 of 6 children receiving S-6437, cephalexin was scarcely detected in their blood in 12 hours after the administration. From this, it is not considered that S-6437 is accumulated in body. 2) S-6437 was administered to 38 patients including: 7 with pneumonia, 7 with acute bronchitis, 1 with suppurative lymphadenitis, 4 with acute pharyngitis, 15 with acute tonsillitis and 4 with acute urinary tract infections. Out of the 35 cases, 31 (88.6%) responded to S-6437, and 3 cases could not be evaluated. 3) Transient diarrhea in 2 patients, rash in 1 and elevation of serum GOT, GPT and LDH in 1 were observed. However, these side effects were improved by discontinuation of S-6437.